B-intervention	0	10	Ribociclib
I-intervention	11	15	plus
I-intervention	16	27	fulvestrant
O	28	31	for
O	32	46	postmenopausal
O	47	52	women
O	53	57	with
O	58	65	hormone
O	66	74	receptor
O	74	75	-
O	75	83	positive
O	83	84	,
O	85	90	human
O	91	100	epidermal
O	101	107	growth
O	108	114	factor
O	115	123	receptor
O	124	125	2
O	125	126	-
O	126	134	negative
O	135	143	advanced
O	144	150	breast
O	151	157	cancer
O	158	160	in
O	161	164	the
O	165	170	phase
O	171	174	III
O	175	185	randomized
O	186	195	MONALEESA
O	195	196	-
O	196	197	3
O	198	203	trial
O	203	204	:
O	205	212	updated
O	213	220	overall
O	221	229	survival
O	229	230	.

O	231	241	Ribociclib
O	242	246	plus
O	247	258	fulvestrant
O	259	271	demonstrated
O	272	283	significant
O	284	295	progression
O	295	296	-
O	296	300	free
O	301	309	survival
O	310	311	(
O	311	314	PFS
O	314	315	)
O	316	319	and
O	320	327	overall
O	328	336	survival
O	337	338	(
O	338	340	OS
O	340	341	)
O	342	350	benefits
O	351	353	in
O	354	362	patients
O	363	367	with
O	368	375	hormone
O	376	384	receptor
O	384	385	-
O	385	393	positive
O	393	394	,
O	395	400	human
O	401	410	epidermal
O	411	417	growth
O	418	424	factor
O	425	433	receptor
O	434	435	2
O	435	436	-
O	436	444	negative
O	445	446	(
O	446	448	HR
O	448	449	+
O	449	450	/
O	450	454	HER2
O	454	455	-
O	455	456	)
O	457	465	advanced
O	466	472	breast
O	473	479	cancer
O	480	481	(
O	481	484	ABC
O	484	485	)
O	485	486	.

O	487	491	Here
O	492	494	we
O	495	502	present
O	503	504	a
O	505	508	new
O	509	517	landmark
O	518	520	in
O	521	529	survival
O	530	536	follow
O	536	537	-
O	537	539	up
O	540	543	for
O	544	545	a
O	546	551	phase
O	552	555	III
O	556	562	cyclin
O	562	563	-
O	563	572	dependent
O	573	580	kinases
O	581	582	4
O	583	586	and
O	587	588	6
O	589	598	inhibitor
O	599	607	clinical
O	608	613	trial
O	614	616	in
O	617	625	patients
O	626	630	with
O	631	634	ABC
O	635	636	(
O	636	642	median
O	642	643	,
O	644	646	56
O	646	647	.
O	647	648	3
O	649	655	months
O	655	656	)
O	656	657	.

O	658	662	This
O	663	668	phase
O	669	672	III
O	672	673	,
O	674	684	randomized
O	684	685	,
O	686	692	double
O	692	693	-
O	693	698	blind
O	698	699	,
O	700	707	placebo
O	707	708	-
O	708	718	controlled
O	719	724	trial
O	725	728	was
O	729	738	conducted
O	739	741	at
O	742	745	174
O	746	751	sites
O	752	753	(
O	753	755	30
O	756	765	countries
O	765	766	)
O	766	767	.

O	768	776	Patients
O	777	781	were
B-eligibility	782	785	men
I-eligibility	786	789	and
I-eligibility	790	804	postmenopausal
I-eligibility	805	810	women
I-eligibility	811	812	(
I-eligibility	812	815	age
I-eligibility	816	817	≥
I-eligibility	817	819	18
I-eligibility	820	825	years
I-eligibility	825	826	)
I-eligibility	827	831	with
I-eligibility	832	846	histologically
I-eligibility	846	847	/
I-eligibility	847	860	cytologically
I-eligibility	861	870	confirmed
I-eligibility	871	873	HR
I-eligibility	873	874	+
I-eligibility	874	875	/
I-eligibility	875	879	HER2
I-eligibility	879	880	-
I-eligibility	881	884	ABC
O	884	885	.

O	886	894	Patients
O	895	900	could
O	901	905	have
O	906	914	received
O	915	916	≤
O	916	917	1
O	918	922	line
O	923	925	of
O	926	935	endocrine
O	936	943	therapy
O	944	945	(
O	945	947	ET
O	947	948	)
O	949	952	but
O	953	955	no
O	956	968	chemotherapy
O	969	972	for
O	973	976	ABC
O	976	977	.

O	978	986	Patients
O	986	987	,
O	988	996	assigned
O	997	998	2
O	998	999	:
O	999	1000	1
O	1000	1001	,
O	1002	1006	were
O	1007	1017	stratified
O	1018	1020	by
O	1021	1024	the
O	1025	1033	presence
O	1033	1034	/
O	1034	1041	absence
O	1042	1044	of
O	1045	1050	liver
O	1050	1051	/
O	1051	1055	lung
O	1056	1066	metastases
O	1067	1070	and
O	1071	1079	previous
O	1080	1082	ET
O	1082	1083	.

O	1084	1092	Patients
O	1093	1101	received
O	1102	1115	intramuscular
O	1116	1127	fulvestrant
O	1128	1129	(
O	1129	1132	500
O	1133	1135	mg
O	1135	1136	,
O	1137	1140	day
O	1141	1142	1
O	1143	1145	of
O	1146	1150	each
O	1151	1153	28
O	1153	1154	-
O	1154	1157	day
O	1158	1163	cycle
O	1164	1168	plus
O	1169	1172	day
O	1173	1175	15
O	1176	1178	of
O	1179	1184	cycle
O	1185	1186	1
O	1186	1187	)
O	1188	1192	with
O	1193	1197	oral
O	1198	1208	ribociclib
O	1209	1210	(
O	1210	1213	600
O	1214	1216	mg
O	1216	1217	/
O	1217	1220	day
O	1220	1221	,
O	1222	1223	3
O	1224	1229	weeks
O	1230	1232	on
O	1232	1233	,
O	1234	1235	1
O	1236	1240	week
O	1241	1244	off
O	1244	1245	)
O	1246	1248	or
B-control	1249	1256	placebo
O	1256	1257	.

O	1258	1266	Efficacy
O	1267	1275	analyses
O	1276	1280	were
O	1281	1283	by
O	1284	1293	intention
O	1294	1296	to
O	1297	1302	treat
O	1302	1303	.

O	1304	1310	Safety
O	1311	1314	was
O	1315	1323	assessed
O	1324	1326	in
O	1327	1335	patients
O	1336	1345	receiving
O	1346	1347	≥
O	1347	1348	1
O	1349	1353	dose
O	1354	1359	study
O	1360	1369	treatment
O	1369	1370	.

B-outcome-Measure	1371	1373	OS
O	1374	1377	was
O	1378	1379	a
O	1380	1389	secondary
O	1390	1398	endpoint
O	1398	1399	.

O	1400	1409	MONALEESA
O	1409	1410	-
O	1410	1411	3
O	1412	1414	is
O	1415	1425	registered
O	1426	1430	with
O	1431	1445	ClinicalTrials
O	1445	1446	.
O	1447	1450	gov
O	1451	1452	(
O	1452	1463	NCT02422615
O	1463	1464	;
O	1465	1467	no
O	1468	1474	longer
O	1475	1484	enrolling
O	1484	1485	)
O	1485	1486	.

O	1487	1494	Between
O	1495	1497	18
O	1498	1502	June
O	1503	1507	2015
O	1508	1511	and
O	1512	1514	10
O	1515	1519	June
O	1520	1524	2016
O	1524	1525	,
B-total-participants	1526	1529	726
O	1530	1538	patients
O	1539	1543	were
O	1544	1552	randomly
O	1553	1561	assigned
O	1562	1563	(
B-intervention-participants	1563	1566	484
O	1566	1567	,
O	1568	1578	ribociclib
O	1578	1579	;
B-control-participants	1580	1583	242
O	1583	1584	,
O	1585	1592	placebo
O	1592	1593	)
O	1593	1594	.

O	1595	1597	At
O	1598	1602	data
O	1603	1606	cut
O	1606	1607	-
O	1607	1610	off
O	1611	1612	(
O	1612	1614	30
O	1615	1622	October
O	1623	1627	2020
O	1627	1628	)
O	1628	1629	,
B-outcome	1630	1636	median
I-outcome	1637	1639	OS
I-outcome	1640	1641	(
I-outcome	1641	1644	mOS
I-outcome	1644	1645	)
O	1646	1649	was
B-iv-cont-median	1650	1652	53
I-iv-cont-median	1652	1653	.
I-iv-cont-median	1653	1654	7
I-iv-cont-median	1655	1661	months
O	1662	1663	(
O	1663	1673	ribociclib
O	1673	1674	)
O	1675	1681	versus
B-cv-cont-median	1682	1684	41
I-cv-cont-median	1684	1685	.
I-cv-cont-median	1685	1686	5
I-cv-cont-median	1687	1693	months
O	1694	1695	(
O	1695	1702	placebo
O	1702	1703	)
O	1704	1705	[
O	1705	1711	hazard
O	1712	1717	ratio
O	1718	1719	(
O	1719	1721	HR
O	1721	1722	)
O	1722	1723	,
O	1724	1725	0
O	1725	1726	.
O	1726	1728	73
O	1728	1729	;
O	1730	1732	95
O	1732	1733	%
O	1734	1744	confidence
O	1745	1753	interval
O	1754	1755	(
O	1755	1757	CI
O	1757	1758	)
O	1759	1760	0
O	1760	1761	.
O	1761	1763	59
O	1763	1764	-
O	1764	1765	0
O	1765	1766	.
O	1766	1768	90
O	1768	1769	]
O	1769	1770	.

O	1771	1779	Subgroup
O	1780	1788	analyses
O	1789	1793	were
O	1794	1804	consistent
O	1805	1809	with
O	1810	1817	overall
O	1818	1828	population
O	1828	1829	.

O	1830	1832	In
O	1833	1836	the
O	1837	1842	first
O	1842	1843	-
O	1843	1847	line
O	1848	1855	setting
O	1855	1856	,
O	1857	1861	most
O	1862	1870	patients
O	1871	1873	in
O	1874	1877	the
O	1878	1888	ribociclib
O	1889	1892	arm
O	1893	1894	(
O	1894	1895	∼
O	1895	1897	60
O	1897	1898	%
O	1898	1899	)
O	1900	1905	lived
O	1906	1912	longer
O	1913	1917	than
O	1918	1924	median
O	1925	1931	follow
O	1931	1932	-
O	1932	1934	up
O	1934	1935	;
B-outcome	1936	1939	mOS
O	1940	1943	was
B-cv-cont-median	1944	1946	51
I-cv-cont-median	1946	1947	.
I-cv-cont-median	1947	1948	8
I-cv-cont-median	1949	1955	months
O	1956	1958	in
O	1959	1962	the
O	1963	1970	placebo
O	1971	1974	arm
O	1975	1976	(
O	1976	1978	HR
O	1978	1979	,
O	1980	1981	0
O	1981	1982	.
O	1982	1984	64
O	1984	1985	;
O	1986	1988	95
O	1988	1989	%
O	1990	1992	CI
O	1993	1994	0
O	1994	1995	.
O	1995	1997	46
O	1997	1998	-
O	1998	1999	0
O	1999	2000	.
O	2000	2002	88
O	2002	2003	)
O	2003	2004	.

O	2005	2007	In
O	2008	2011	the
O	2012	2018	second
O	2018	2019	-
O	2019	2023	line
O	2024	2031	setting
O	2031	2032	,
B-outcome	2033	2036	mOS
O	2037	2040	was
B-iv-cont-median	2041	2043	39
I-iv-cont-median	2043	2044	.
I-iv-cont-median	2044	2045	7
I-iv-cont-median	2046	2052	months
O	2053	2054	(
O	2054	2064	ribociclib
O	2064	2065	)
O	2066	2072	versus
B-cv-cont-median	2073	2075	33
I-cv-cont-median	2075	2076	.
I-cv-cont-median	2076	2077	7
I-cv-cont-median	2078	2084	months
O	2085	2086	(
O	2086	2093	placebo
O	2093	2094	)
O	2095	2096	(
O	2096	2098	HR
O	2098	2099	,
O	2100	2101	0
O	2101	2102	.
O	2102	2104	78
O	2104	2105	;
O	2106	2108	95
O	2108	2109	%
O	2110	2112	CI
O	2113	2114	0
O	2114	2115	.
O	2115	2117	59
O	2117	2118	-
O	2118	2119	1
O	2119	2120	.
O	2120	2122	04
O	2122	2123	)
O	2123	2124	.

O	2125	2127	No
O	2128	2136	apparent
O	2137	2141	drug
O	2141	2142	-
O	2142	2146	drug
O	2147	2158	interaction
O	2159	2166	between
O	2167	2177	ribociclib
O	2178	2181	and
O	2182	2193	fulvestrant
O	2194	2196	or
O	2197	2200	new
O	2201	2207	safety
O	2208	2215	signals
O	2216	2220	were
O	2221	2229	observed
O	2229	2230	.

O	2231	2235	This
O	2236	2244	analysis
O	2245	2253	reported
O	2254	2262	extended
O	2263	2265	OS
O	2266	2272	follow
O	2272	2273	-
O	2273	2275	up
O	2276	2278	in
O	2279	2288	MONALEESA
O	2288	2289	-
O	2289	2290	3
O	2290	2291	.

O	2292	2295	mOS
O	2296	2299	was
O	2300	2301	∼
O	2301	2303	12
O	2304	2310	months
O	2311	2317	longer
O	2318	2320	in
O	2321	2329	patients
O	2330	2334	with
O	2335	2337	HR
O	2337	2338	+
O	2338	2339	/
O	2339	2343	HER2
O	2343	2344	-
O	2345	2348	ABC
O	2349	2356	treated
O	2357	2361	with
O	2362	2372	ribociclib
O	2373	2377	plus
O	2378	2389	fulvestrant
O	2390	2398	compared
O	2399	2403	with
O	2404	2415	fulvestrant
O	2416	2427	monotherapy
O	2427	2428	.
